LOGIN
Denosumab is superior to alendronate for improving cortical bone porosity post-menopause
June 2014
Denosumab is superior to alendronate for improving cortical bone porosity post-menopause
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Differing effects of denosumab and alendronate on cortical and trabecular bone
Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Two hundred and forty-seven post-menopausal women (146 with data at final follow-up) received a subcutaneous injection every 6 months and a pill weekly. These treatments were randomized as follows: Group one received denosumab injections and a placebo pill, Group two received alendronate and a placebo injection and Group three received a placebo injection and pill. The purpose of this trial wa...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.